Novo completes phase 2 CagriSema kidney trial in CKD and type 2 diabetes
The study compared CagriSema 2.4 mg/2.4 mg weekly against semaglutide, cagrilintide alone and placebo over roughly 35 weeks.
PR
By Priya Raman · Science Reporter
Sep 24 08:00 ETSource: ClinicalTrials.gov
The wire
- 01NCT06131372, sponsored by Novo Nordisk, is listed as completed; it randomized people with chronic kidney disease, type 2 diabetes and overweight or obesity to CagriSema, semaglutide 2.4 mg, cagrilintide 2.4 mg or placebo, starting April 2024.
- 02The design isolates the amylin analog cagrilintide's contribution to kidney damage endpoints, relevant to clinicians tracking incretin and amylin effects beyond weight and glycemia.
- 03No results are posted in the registry entry; the 35-week phase 2 duration limits what can be said about durable renal outcomes.
From the source
Read at clinicaltrials.govA Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT06131372 · PHASE2 · COMPLETED · Sponsor: Novo Nordisk A/S · Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity.
Source URL https://clinicaltrials.gov/study/NCT06131372
